Iovance Biotherapeutics (IOVA) earnings

IOVANCE BIOTHERAPEUTICS, INC.

Results to: Jun 2026
Latest analysed call: Jun 2026 (Q2 FY26)
Balance sheet to: Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Iovance Biotherapeutics earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	99.3 $ million	+65.7% YoY	Quarterly, as filed	Quarter to Jun 2026	Revenue from operations as filed.
Operating margin	-52.3 %	+137.5 pts YoY	Operating profit / revenue	Quarter to Jun 2026	For the quarter; a change is in percentage points.
Net profit	-47.3 $ million	—	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Price

$14.72 +3.59% · +$0.51

Last close Oct 15, 2026 · US · USD

Performance +594.3% 1Y

1Y: $2.12 on 14 Oct 2025 → $14.72. High $14.82 (30 Sept 2026), low $1.81 (5 Nov 2025).

Previous close: $14.21
52-week range: $1.81 – $14.82
One year: +557.14%

Overview

Symbol: IOVA
Exchange: US
Currency: USD

Financials

What the filings say

Net profit, year on year: +58% (quarter to jun 2026 against jun 2025).

In $ million. Oldest period first.

Line item	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	59	74	49	60	67	87	71	99
Expenses	148	160	171	174	162	160	152	151
Operating profit	-89	-87	-121	-114	-95	-73	-81	-52
Operating margin	−152.1%	−117.5%	−245.8%	−189.8%	−140.7%	−84.7%	−113.5%	−52.3%
Profit before tax	-85	-77	-118	-110	-94	-72	-80	-49
Tax rate	1.8%	−2.0%	1.6%	−1.8%	2.6%	−0.3%	0.8%	2.8%
Net profit	-84	-79	-116	-112	-91	-72	-79	-47
EPS ($ per share)	-0.28	—	-0.36	-0.33	-0.25	—	-0.19	-0.11

Source: Inve data · income statement, quarterly · to Jun 2026

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Equity capital	0	0	0	0	0	0	0	0
Reserves	-373	-571	-830	-1,172	-1,568	-2,012	-2,385	-2,776
Total liabilities	15	46	112	156	164	196	200	215
Fixed assets	3	9	59	101	105	114	109	131
Investments	386	293	562	426	240	165	208	134
Total assets	481	345	768	777	664	780	910	913

Source: Inve data · balance sheet · to Dec 2025

In $ million. Oldest period first.

Line item	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from operations	-101	-159	-205	-228	-293	-362	-353	-302
Cash from investing	-386	90	-318	0	256	-155	-96	47
Cash from financing	424	6	576	239	190	463	391	301
Net cash flow	—	—	—	11	154	-57	-59	47
Capital expenditure	-1	-7	-47	-38	-20	-22	-11	-34
Free cash flow	-102	-166	-252	-266	-313	-384	-364	-336

Source: Inve data · cash flow · to Dec 2025

IOVA revenue by segment

IOVA revenue by business segment, share of consolidated revenue by quarter
Segment	Q2 FY2024	Q3 FY2024	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025	Q1 FY2026	Q2 FY2026	YoY growth latest quarter
Single Reportable	—	—	100%	100%	100%	100%	100%	100%	+65.7%

Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.

See how segments are shifting across companies → Segment Shift

Revenue by region

Q2 FY2026 · share of revenue

US 100% ↑ 1 pt
Non Us <1% ↓ 1 pt

As IOVA cuts its regions in its filings; they can nest, so they need not add to 100%.

Insider filings

68 filings between Dec 1, 2025 and Sep 8, 2026.

Open market

decisions to buy or sell

Nobody bought or sold IOVA on the open market in this window. The filings below are 34 option exercises and 34 tax withholdings.

Compensation

not trading decisions

34: Option exercise — converted options into shares
34: Tax withheld — shares kept back by the company to cover tax

Latest filings (50)

Date	Insider	What	Shares	Value
Sep 8, 2026	Vogt Frederick G Interim CEO & General Counsel	Tax withheld	6,638	$57.8K
Sep 8, 2026	Puri Raj K. Chief Regulatory Officer	Option exercise	9,766	$0
Sep 8, 2026	BILINSKY IGOR Chief Operating Officer	Option exercise	7,813	$0
Sep 8, 2026	Vogt Frederick G Interim CEO & General Counsel	Option exercise	15,626	$0
Sep 8, 2026	BILINSKY IGOR Chief Operating Officer	Tax withheld	3,976	$34.6K
Sep 8, 2026	Puri Raj K. Chief Regulatory Officer	Tax withheld	4,478	$39.0K
Sep 1, 2026	Puri Raj K. Chief Regulatory Officer	Option exercise	5,470	$0
Sep 1, 2026	BILINSKY IGOR Chief Operating Officer	Option exercise	8,789	$0
Sep 1, 2026	Vogt Frederick G Interim CEO & General Counsel	Option exercise	41,669	$0
Sep 1, 2026	BILINSKY IGOR Chief Operating Officer	Tax withheld	4,472	$37.0K
Sep 1, 2026	Puri Raj K. Chief Regulatory Officer	Tax withheld	2,508	$20.8K
Sep 1, 2026	Vogt Frederick G Interim CEO & General Counsel	Tax withheld	17,702	$146.6K
Aug 10, 2026	Kirby Daniel Gordon Chief Commercial Officer	Option exercise	10,001	$0
Aug 10, 2026	Kirby Daniel Gordon Chief Commercial Officer	Tax withheld	2,436	$15.6K
Aug 6, 2026	Roche Corleen M. Chief Financial Officer	Tax withheld	21,238	$131.9K
Aug 6, 2026	Roche Corleen M. Chief Financial Officer	Option exercise	49,995	$0
Jun 5, 2026	BILINSKY IGOR Chief Operating Officer	Option exercise	7,813	$0
Jun 5, 2026	Puri Raj K. Chief Regulatory Officer	Option exercise	9,766	$0
Jun 5, 2026	Vogt Frederick G Interim CEO & General Counsel	Tax withheld	6,638	$28.1K
Jun 5, 2026	BILINSKY IGOR Chief Operating Officer	Tax withheld	3,976	$16.8K
Jun 5, 2026	Vogt Frederick G Interim CEO & General Counsel	Option exercise	15,625	$0
Jun 5, 2026	GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer	Tax withheld	3,976	$16.8K
Jun 5, 2026	GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer	Option exercise	7,813	$0
Jun 5, 2026	Puri Raj K. Chief Regulatory Officer	Tax withheld	3,843	$16.3K
Jun 1, 2026	GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer	Option exercise	8,790	$0
Jun 1, 2026	BILINSKY IGOR Chief Operating Officer	Tax withheld	4,473	$17.7K
Jun 1, 2026	GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer	Tax withheld	4,473	$17.7K
Jun 1, 2026	BILINSKY IGOR Chief Operating Officer	Option exercise	8,790	$0
Jun 1, 2026	Vogt Frederick G Interim CEO & General Counsel	Tax withheld	17,701	$70.1K
Jun 1, 2026	Vogt Frederick G Interim CEO & General Counsel	Option exercise	41,668	$0
Jun 1, 2026	Puri Raj K. Chief Regulatory Officer	Tax withheld	2,508	$9.9K
Jun 1, 2026	Puri Raj K. Chief Regulatory Officer	Option exercise	5,469	$0
May 11, 2026	Kirby Daniel Gordon Chief Commercial Officer	Tax withheld	2,435	$9.0K
May 11, 2026	Kirby Daniel Gordon Chief Commercial Officer	Option exercise	10,000	$0
Mar 5, 2026	Vogt Frederick G Interim CEO & General Counsel	Tax withheld	26,755	$122.5K
Mar 5, 2026	GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer	Tax withheld	16,520	$75.7K
Mar 5, 2026	Vogt Frederick G Interim CEO & General Counsel	Option exercise	62,493	$0
Mar 5, 2026	BILINSKY IGOR Chief Operating Officer	Tax withheld	16,628	$76.2K
Mar 5, 2026	GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer	Option exercise	31,246	$0
Mar 5, 2026	Puri Raj K. Chief Regulatory Officer	Tax withheld	18,360	$84.1K
Mar 5, 2026	BILINSKY IGOR Chief Operating Officer	Option exercise	31,246	$0
Mar 5, 2026	Puri Raj K. Chief Regulatory Officer	Option exercise	39,059	$0
Mar 2, 2026	GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer	Option exercise	12,697	$0
Mar 2, 2026	Vogt Frederick G Interim CEO & General Counsel	Tax withheld	22,809	$86.4K
Mar 2, 2026	BILINSKY IGOR Chief Operating Officer	Tax withheld	6,903	$26.2K
Mar 2, 2026	Vogt Frederick G Interim CEO & General Counsel	Option exercise	52,087	$0
Mar 2, 2026	Puri Raj K. Chief Regulatory Officer	Option exercise	5,470	$0
Mar 2, 2026	BILINSKY IGOR Chief Operating Officer	Option exercise	12,307	$0
Mar 2, 2026	Puri Raj K. Chief Regulatory Officer	Tax withheld	2,798	$10.6K
Mar 2, 2026	GRAF FINCKENSTEIN FRIEDRICH Chief Medical Officer	Tax withheld	7,122	$27.0K

Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.

Your own record

Start an Inve Case for IOVANCE BIOTHERAPEUTICS, INC.

Free account. Everything above stays public.

Write why you follow IOVANCE BIOTHERAPEUTICS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

Create your Inve Case What an account adds

Keep reading